Erratum to: Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: Data from the CERERRA collaboration [Arthritis Res Ther. 18: (2016); 50], doi: 10.1186/s13075-016-0951-z;Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: Data from the CERERRA collaboration

Arthritis Research and Therapy

Volumn 18, Issue 1, 2016, Pages

  Chatzidionysiou, Katerina ^a   Lie, Elisabeth ^b   Nasonov, Evgeny ^c   Lukina, Galina ^c   Hetland, Merete Lund ^d   Tarp, Ulrik ^e   Ancuta, Ioan ^f   Pavelka, Karel ^g   Nordström, Dan C ^h   Gabay, Cem ⁱ   Canhão, Helene ^j   Tomsic, Matija ^k   van Riel, Piet L C M ^l   Gomez Reino, Juan ^m   Kvien, Tore K ^b   Vollenhoven, Ronald F ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b DIAKONHJEMMET HOSPITAL   (Norway)

^c V A NASONOVA RESEARCH INSTITUTE OF RHEUMATOLOGY   (Russian Federation)

^d Copenhagen University Hospital at Glostrup ^*  (Denmark)

^e AARHUS UNIVERSITY HOSPITAL   (Denmark)

^f CANTACUZINO INSTITUTE   (Romania)

^g CHARLES UNIVERSITY   (Czech Republic)

^h HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

ⁱ GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^j INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^k UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^l RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^m Pediatric Nutrition Research Group Health Research Institute of Santiago de Compostela   (Spain)

more..

Author keywords

Observational; Rheumatoid arthritis; Rituximab

Indexed keywords

CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; RITUXIMAB; ANTIRHEUMATIC AGENT;

ADULT; ARTICLE; COHORT ANALYSIS; DEMOGRAPHY; DISEASE DURATION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; REMISSION; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME; TREATMENT PLANNING; AGED; ARTHRITIS, RHEUMATOID; COOPERATION; EUROPE; FACTUAL DATABASE; INTERNATIONAL COOPERATION; MIDDLE AGED; PROCEDURES; REGISTER; STATISTICS;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; COOPERATIVE BEHAVIOR; DATABASES, FACTUAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EUROPE; FEMALE; HUMANS; INTERNATIONALITY; MALE; MIDDLE AGED; REGISTRIES; RITUXIMAB; STATISTICS AS TOPIC; TREATMENT OUTCOME;

EID: 84957991509     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/s13075-016-1048-4     Document Type: Erratum

References (16)

1. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54:2793-806.
2. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350:2572-81.
3. Vander Cruyssen B, Durez P, Westhovens R, Kaiser MJ, Hoffman I, De Keyser F, et al. The Belgian MIRA (MabThera In Rheumatoid Arthritis) registry: clues for the optimization of rituximab treatment strategies. Arthritis Res Ther. 2010;12:R169.
4. Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, et al. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Ann Rheum Dis. 2011;70:1575-80.
5. Emery P, Deodhar A, Rigby WF, Isaacs JD, Combe B, Racewicz AJ, et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis. 2010;69:1629-35.
6. Rubbert-Roth A, Tak PP, Zerbini C, Tremblay JL, Carreno L, Armstrong G, et al. Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR). Rheumatology (Oxford). 2010;49:1683-93.
7. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 2006;54:1390-400.
8. Tak PP, Rigby WF, Rubbert-Roth A, Peterfy CG, van Vollenhoven RF, Stohl W, et al. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis. 2011;70:39-46.
9. Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, et al. Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration. Ann Rheum Dis. 2012;71:374-7.
10. Bredemeier M, de Oliveira FK, Rocha CM. Low- versus high-dose rituximab for rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2014;66:228-35.
11. Leandro MJ, Edwards JC, Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis. 2002;61:883-8.
12. Vital EM, Rawstron AC, Dass S, Henshaw K, Madden J, Emery P, et al. Reduced-dose rituximab in rheumatoid arthritis: efficacy depends on degree of B cell depletion. Arthritis Rheum. 2011;63:603-8.
13. Leandro MJ. B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies. Arthritis Res Ther. 2013;15 Suppl 1:S3.
14. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83:435-45.
15. Maloney DG, Liles TM, Czerwinski DK, Waldichuk C, Rosenberg J, Grillo-Lopez A, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood. 1994;84:2457-66.
16. Tak PP, Rigby W, Rubbert-Roth A, Peterfy C, van Vollenhoven RF, Stohl W, et al. Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE. Ann Rheum Dis. 2012;71:351-7.